Skip to Content
You are currently on the new version of our website. Access the old version .

43 Results Found

  • Review
  • Open Access
82 Citations
10,744 Views
23 Pages

An Overview of Sub-Cellular Mechanisms Involved in the Action of TTFields

  • Jack A. Tuszynski,
  • Cornelia Wenger,
  • Douglas E. Friesen and
  • Jordane Preto

Long-standing research on electric and electromagnetic field interactions with biological cells and their subcellular structures has mainly focused on the low- and high-frequency regimes. Biological effects at intermediate frequencies between 100 and...

(This article belongs to the Special Issue Biological and Health Effects of Low Level Non-Ionising Electromagnetic Fields)
  • Case Report
  • Open Access
6 Citations
3,798 Views
9 Pages

TTFields Prolonged the PFS of Epithelioid Glioblastoma Patient: A Case Report

  • Yuxuan Ding,
  • Qiang Wang,
  • Feijiang Wang,
  • Nan Wu and ,
  • Jianrui Li,
  • Xia He,
  • Hao Pan and
  • Lijun Wang
  • + 3 authors+ 0 author

Epithelioid glioblastoma (EGBM, classified as glioblastoma, IDH wild type, grade 4 according to the fifth edition of the World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS) (WHO CNS5)) is a highly aggressive m...

(This article belongs to the Section Molecular and Cellular Neuroscience)
  • Review
  • Open Access
21 Citations
10,229 Views
19 Pages

Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment

  • Ignace Vergote,
  • Teresa Macarulla,
  • Fred R. Hirsch,
  • Carsten Hagemann and
  • David Scott Miller

19 January 2023

Non-small cell lung cancer, ovarian cancer, and pancreatic cancer all present with high morbidity and mortality. Systemic chemotherapies have historically been the cornerstone of standard of care (SOC) regimens for many cancers, but are associated wi...

(This article belongs to the Collection Combination Therapies in Cancers)
  • Article
  • Open Access
4 Citations
1,496 Views
20 Pages

Pro-Inflammatory Macrophage Phenotype Skewing Induced by Tumor Treating Fields (TTFields)

  • Tal Kan,
  • Yiftah Barsheshet,
  • Tharwat Haj Khalil,
  • Boris Brant and ,
  • Tali Voloshin,
  • Kerem Ben-Meir,
  • Simona Zisman Rosen,
  • Moshe Giladi,
  • Uri Weinberg and
  • Yoram Palti
  • + 5 authors+ 0 author

16 December 2025

Tumor-associated macrophages (TAMs) are abundant in the tumor microenvironment (TME) and often adopt an M2-like immunosuppressive phenotype that promotes tumor growth. Reprogramming TAMs toward an M1-like pro-inflammatory state is an attractive thera...

(This article belongs to the Section Molecular Immunology)
  • Article
  • Open Access
35 Citations
4,833 Views
15 Pages

Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo

  • Shiri Davidi,
  • Sara Jacobovitch,
  • Anna Shteingauz,
  • Antonia Martinez-Conde and ,
  • Ori Braten,
  • Catherine Tempel-Brami,
  • Einav Zeevi,
  • Roni Frechtel-Gerzi,
  • Hila Ene and
  • Yoram Palti
  • + 12 authors+ 7 authors

15 June 2022

Hepatocellular carcinoma (HCC), a highly aggressive liver cancer, is a leading cause of cancer-related death. Tumor Treating Fields (TTFields) are electric fields that exert antimitotic effects on cancerous cells. The aims of the current research wer...

(This article belongs to the Collection Novel Therapies for Hepatocellular Carcinoma)
  • Article
  • Open Access
45 Citations
8,947 Views
20 Pages

Tumor Treating Fields (TTFields) Reversibly Permeabilize the Blood–Brain Barrier In Vitro and In Vivo

  • Ellaine Salvador,
  • Almuth F. Kessler,
  • Dominik Domröse,
  • Julia Hörmann and ,
  • Clara Schaeffer,
  • Aiste Giniunaite,
  • Malgorzata Burek,
  • Catherine Tempel-Brami,
  • Tali Voloshin and
  • Carsten Hagemann
  • + 11 authors+ 6 authors

22 September 2022

Despite the availability of numerous therapeutic substances that could potentially target CNS disorders, an inability of these agents to cross the restrictive blood–brain barrier (BBB) limits their clinical utility. Novel strategies to overcome...

(This article belongs to the Special Issue Regulation of the Endothelial Cell Barrier)
  • Article
  • Open Access
3 Citations
5,381 Views
19 Pages

Optimized Methods to Quantify Tumor Treating Fields (TTFields)-Induced Permeabilization of Glioblastoma Cell Membranes

  • Melisa Martinez-Paniagua,
  • Sabbir Khan,
  • Nikita W. Henning,
  • Sri Vaishnavi Konagalla and
  • Chirag B. Patel

22 January 2025

Glioblastoma (GBM) is a lethal primary brain cancer with a 5.6% five-year survival rate. Tumor treating fields (TTFields) are alternating low-intensity electric fields that have demonstrated a GBM patient survival benefit. We previously reported that...

(This article belongs to the Section Molecular and Cellular Biology)
  • Brief Report
  • Open Access
5 Citations
3,687 Views
6 Pages

Tumor Treating Fields (TTFields) therapy is FDA approved and has the CE mark for treatment of newly diagnosed and recurrent glioblastoma. To our knowledge, to date TTFields therapy remains unstudied in glioblastoma patients with multiple sclerosis (M...

(This article belongs to the Section Neuro-oncology)
  • Article
  • Open Access
16 Citations
4,330 Views
16 Pages

Glioblastoma-Derived Three-Dimensional Ex Vivo Models to Evaluate Effects and Efficacy of Tumor Treating Fields (TTFields)

  • Vera Nickl,
  • Ellina Schulz,
  • Ellaine Salvador,
  • Laureen Trautmann and ,
  • Leopold Diener,
  • Almuth F. Kessler,
  • Camelia M. Monoranu,
  • Faramarz Dehghani,
  • Ralf-Ingo Ernestus and
  • Carsten Hagemann
  • + 6 authors+ 1 author

22 October 2022

Glioblastoma (GBM) displays a wide range of inter- and intra-tumoral heterogeneity contributing to therapeutic resistance and relapse. Although Tumor Treating Fields (TTFields) are effective for the treatment of GBM, there is a lack of ex vivo models...

(This article belongs to the Section Clinical Research in Cancer)
  • Article
  • Open Access
2 Citations
3,913 Views
14 Pages

21 February 2024

Glioblastoma is an aggressive, incurable brain cancer with poor five-year survival rates of around 13% despite multimodal treatment with surgery, DNA-damaging chemoradiotherapy and the recent addition of Tumour Treating Fields (TTFields). As such, th...

(This article belongs to the Collection Genome Maintenance in Cancer Biology and Therapy)
  • Article
  • Open Access
24 Citations
4,760 Views
12 Pages

Tumor Treating Fields (TTFields) Induce Cell Junction Alterations in a Human 3D In Vitro Model of the Blood-Brain Barrier

  • Ellaine Salvador,
  • Theresa Köppl,
  • Julia Hörmann,
  • Sebastian Schönhärl and ,
  • Polina Bugaeva,
  • Almuth F. Kessler,
  • Malgorzata Burek,
  • Ralf-Ingo Ernestus,
  • Mario Löhr and
  • Carsten Hagemann
  • + 5 authors+ 0 author

In a recent study, we showed in an in vitro murine cerebellar microvascular endothelial cell (cerebEND) model as well as in vivo in rats that Tumor-Treating Fields (TTFields) reversibly open the blood–brain barrier (BBB). This process is facili...

(This article belongs to the Section Gene and Cell Therapy)
  • Article
  • Open Access
44 Citations
7,816 Views
15 Pages

Tumor Treating Fields (TTFields) Concomitant with Immune Checkpoint Inhibitors Are Therapeutically Effective in Non-Small Cell Lung Cancer (NSCLC) In Vivo Model

  • Yiftah Barsheshet,
  • Tali Voloshin,
  • Boris Brant,
  • Gadi Cohen and ,
  • Lilach Koren,
  • Roni Blatt,
  • Shay Cahal,
  • Tharwat Haj Khalil,
  • Efrat Zemer Tov and
  • Yoram Palti
  • + 16 authors+ 11 authors

15 November 2022

Tumor Treating Fields (TTFields) are electric fields that exert physical forces to disrupt cellular processes critical for cancer cell viability and tumor progression. TTFields induce anti-mitotic effects through the disruption of the mitotic spindle...

(This article belongs to the Section Molecular Immunology)
  • Review
  • Open Access
13 Citations
5,344 Views
12 Pages

Research Progress on the Mechanism of Anti-Tumor Immune Response Induced by TTFields

  • Yue Lan,
  • Shaomin Zhang,
  • Yun Pan,
  • Minmin Wang and
  • Guangdi Chen

29 November 2023

Tumor treating fields (TTFields), a biophysical therapy technology that uses alternating electric fields to inhibit tumor proliferation, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of newly diagnosed or recurren...

(This article belongs to the Section Cancer Therapy)
  • Article
  • Open Access
60 Citations
9,893 Views
21 Pages

Alternating Electric Fields (TTFields) Activate Cav1.2 Channels in Human Glioblastoma Cells

  • Eric Neuhaus,
  • Lisa Zirjacks,
  • Katrin Ganser,
  • Lukas Klumpp and ,
  • Uwe Schüler,
  • Daniel Zips,
  • Franziska Eckert and
  • Stephan M. Huber
  • + 3 authors+ 0 author

18 January 2019

Tumor treating fields (TTFields) represent a novel FDA-approved treatment modality for patients with newly diagnosed or recurrent glioblastoma multiforme. This therapy applies intermediate frequency alternating electric fields with low intensity to t...

(This article belongs to the Special Issue Ion Channels in Cancer)
  • Article
  • Open Access
94 Citations
8,389 Views
18 Pages

Tumor Treating Fields (TTFields) Hinder Cancer Cell Motility through Regulation of Microtubule and Actin Dynamics

  • Tali Voloshin,
  • Rosa Sara Schneiderman,
  • Alexandra Volodin,
  • Reuben Ruby Shamir and ,
  • Noa Kaynan,
  • Einav Zeevi,
  • Lilach Koren,
  • Anat Klein-Goldberg,
  • Rom Paz and
  • Yoram Palti
  • + 8 authors+ 3 authors

17 October 2020

Tumor Treating Fields (TTFields) are noninvasive, alternating electric fields within the intermediate frequency range (100–300 kHz) that are utilized as an antimitotic cancer treatment. TTFields are loco-regionally delivered to the tumor region...

(This article belongs to the Special Issue Targeted Therapies for the Treatment of Glioblastoma)
  • Review
  • Open Access
69 Citations
11,266 Views
23 Pages

Tumor-Treating Fields in Glioblastomas: Past, Present, and Future

  • Xiaopeng Guo,
  • Xin Yang,
  • Jiaming Wu,
  • Huiyu Yang and ,
  • Yilin Li,
  • Junlin Li,
  • Qianshu Liu,
  • Chen Wu,
  • Hao Xing and
  • Wenbin Ma
  • + 8 authors+ 3 authors

28 July 2022

Tumor-treating fields (TTFields), a noninvasive and innovative therapeutic approach, has emerged as the fourth most effective treatment option for the management of glioblastomas (GBMs), the most deadly primary brain cancer. According to on recent mi...

  • Review
  • Open Access
17 Citations
8,230 Views
15 Pages

Tumor-Treating Fields Therapy for Pediatric Brain Tumors

  • Atsushi Makimoto,
  • Ryo Nishikawa,
  • Keita Terashima,
  • Jun Kurihara and ,
  • Hiroyuki Fujisaki,
  • Satoshi Ihara,
  • Yoshihiko Morikawa and
  • Yuki Yuza
  • + 3 authors+ 0 author

8 April 2021

Tumor-treating fields (TTFields) are alternating electric fields applied continuously to the brain by attaching two-pair arrays on the scalp. Although TTFields therapy has demonstrated efficacy against supratentorial glioblastoma (GBM) in adults, its...

  • Article
  • Open Access
29 Citations
5,742 Views
15 Pages

Tumor Treating Fields Concomitant with Sorafenib in Advanced Hepatocellular Cancer: Results of the HEPANOVA Phase II Study

  • Eleni Gkika,
  • Anca-Ligia Grosu,
  • Teresa Macarulla Mercade,
  • Antonio Cubillo Gracián and ,
  • Thomas B. Brunner,
  • Michael Schultheiß,
  • Monika Pazgan-Simon,
  • Thomas Seufferlein and
  • Yann Touchefeu
  • + 4 authors+ 0 author

18 March 2022

Advanced hepatocellular carcinoma (HCC) is an aggressive disease associated with poor prognosis. Tumor Treating Fields (TTFields) therapy is a non-invasive, loco-regional treatment approved for glioblastoma and malignant pleural mesothelioma. HCC pre...

(This article belongs to the Collection Novel Therapies for Hepatocellular Carcinoma)
  • Article
  • Open Access
17 Citations
4,274 Views
12 Pages

Feasibility of Tumor Treating Fields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Single-Center, Real-World Data

  • Tugce Kutuk,
  • Haley Appel,
  • Maria Carolina Avendano,
  • Federico Albrecht and ,
  • Paul Kaywin,
  • Suyen Ramos,
  • Melanie E. Suarez-Murias,
  • Minesh P. Mehta and
  • Rupesh Kotecha
  • + 4 authors+ 0 author

16 April 2022

Purpose: The objectives of this study were to evaluate the implementation, device usage rates, clinical outcomes, and treatment-related toxicities associated with TTFields and pemetrexed plus platinum-based chemotherapy in patients with unresectable...

  • Article
  • Open Access
10 Citations
3,900 Views
17 Pages

Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas

  • Dietmar Krex,
  • Paula Bartmann,
  • Doris Lachmann,
  • Alexander Hagstotz and ,
  • Willi Jugel,
  • Rosa S. Schneiderman,
  • Karnit Gotlib,
  • Yaara Porat,
  • Katja Robel and
  • Susanne Michen
  • + 7 authors+ 2 authors

Tumor Treating Fields (TTFields) were incorporated into the treatment of glioblastoma, the most malignant brain tumor, after showing an effect on progression-free and overall survival in a phase III clinical trial. The combination of TTFields and an...

(This article belongs to the Section Molecular Oncology)
  • Review
  • Open Access
65 Citations
9,605 Views
19 Pages

Permeabilizing Cell Membranes with Electric Fields

  • Alondra A. Aguilar,
  • Michelle C. Ho,
  • Edwin Chang,
  • Kristen W. Carlson and ,
  • Arutselvan Natarajan,
  • Tal Marciano,
  • Ze’ev Bomzon and
  • Chirag B. Patel
  • + 3 authors+ 0 author

10 May 2021

The biological impact of exogenous, alternating electric fields (AEFs) and direct-current electric fields has a long history of study, ranging from effects on embryonic development to influences on wound healing. In this article, we focus on the appl...

(This article belongs to the Special Issue Glioblastomas)
  • Communication
  • Open Access
3 Citations
4,018 Views
6 Pages

Multi-Institutional Patterns of Use of Tumor-Treating Fields for Patients with Malignant Pleural Mesothelioma

  • Tugce Kutuk,
  • Joshua M. Walker,
  • Matthew T. Ballo,
  • Robert B. Cameron and ,
  • Jean Bustamante Alvarez,
  • Sheema Chawla,
  • Eric Luk,
  • Deepti Behl,
  • Alan Dal Pra and
  • Rupesh Kotecha
  • + 10 authors+ 5 authors

23 May 2023

(1) Background: The objective of this analysis was to evaluate the device usage rates and patterns of use regarding Tumor-Treating Fields (TTFields) for patients with malignant pleural mesothelioma (MPM) throughout the US. (2) Methods: We evaluated d...

  • Article
  • Open Access
1 Citations
2,405 Views
14 Pages

Safety and Efficacy of Tumor-Treating Fields (TTFields) Therapy for Pediatric High-Grade Glioma: Results of a Prespecified Interim Analysis of the First Three Cases

  • Atsushi Makimoto,
  • Keita Terashima,
  • Ryo Nishikawa,
  • Hiroyuki Fujisaki and ,
  • Jun Kurihara,
  • Satoshi Ihara,
  • Jun-ichi Adachi,
  • Mikako Enokizono,
  • Naoko Mori and
  • Yuki Yuza
  • + 6 authors+ 1 author

6 January 2026

Background/Objectives: Although Tumor-Treating Fields (TTFields) therapy is an established treatment modality for adult glioblastoma, clinical data on its efficacy in pediatric brain tumors are extremely scarce. The present study aimed to evaluate th...

(This article belongs to the Section Pediatric Hematology & Oncology)
  • Article
  • Open Access
7 Citations
2,971 Views
13 Pages

Tumor Treating Fields Alter the Kinomic Landscape in Glioblastoma Revealing Therapeutic Vulnerabilities

  • Amber B. Jones,
  • Taylor L. Schanel,
  • Mikayla R. Rigsby,
  • Corinne E. Griguer and ,
  • Braden C. McFarland,
  • Joshua C. Anderson,
  • Christopher D. Willey and
  • Anita B. Hjelmeland
  • + 3 authors+ 0 author

30 August 2023

Treatment for the deadly brain tumor glioblastoma (GBM) has been improved through the non-invasive addition of alternating electric fields, called tumor treating fields (TTFields). Improving both progression-free and overall survival, TTFields are cu...

(This article belongs to the Section Cellular Pathology)
  • Article
  • Open Access
58 Citations
6,792 Views
18 Pages

Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy

  • Yunhui Jo,
  • Eun Ho Kim,
  • Sei Sai,
  • Jin Su Kim and ,
  • Jae-Min Cho,
  • Hyeongi Kim,
  • Jeong-Hwa Baek,
  • Jeong-Yub Kim,
  • Sang-Gu Hwang and
  • Myonggeun Yoon
  • + 5 authors+ 0 author

21 November 2018

Glioblastoma, the most common primary brain tumor in adults, is an incurable malignancy with poor short-term survival and is typically treated with radiotherapy along with temozolomide. While the development of tumor-treating fields (TTFields), elect...

(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
  • Review
  • Open Access
1,294 Views
13 Pages

Combining Tumor Treating Fields with Immunotherapy in Pancreatic Ductal Adenocarcinoma: Mechanisms, Preclinical Evidence, and Emerging Therapeutic Synergy

  • Douaa Albelal,
  • Hari Krishnareddy Rachamala,
  • Ishita Saha,
  • Santanu Bhattacharya and ,
  • Debabrata Mukhopadhyay and
  • Hani M. Babiker
  • + 1 author+ 0 author

5 May 2026

Tumor Treating Fields (TTFields) represent a novel, non-invasive therapeutic modality in oncology that employs low-intensity, intermediate-frequency alternating electric fields to disrupt mitotic processes and induce cancer cell death. This review in...

  • Article
  • Open Access
25 Citations
5,449 Views
11 Pages

Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center

  • Chunjui Chen,
  • Hao Xu,
  • Kun Song,
  • Yi Zhang and ,
  • Junyan Zhang,
  • Yang Wang,
  • Xiaofang Sheng,
  • Lingchao Chen and
  • Zhiyong Qin
  • + 4 authors+ 0 author

3 October 2022

Introduction: TTFields plus Temozolomide (TTFields/TMZ) extended survival versus TMZ alone in newly diagnosed glioblastoma (GBM) patients in the EF-14 trial. We have reported a retrospective analysis of newly diagnosed Chinese GBM patients who receiv...

(This article belongs to the Special Issue The Recent Updates in Glioblastoma Management)
  • Article
  • Open Access
34 Citations
11,808 Views
18 Pages

5-Fluorouracil as a Tumor-Treating Field-Sensitizer in Colon Cancer Therapy

  • Yeon-Joo Lee,
  • Jae-Min Cho,
  • Sei Sai,
  • Ju Yeon Oh and ,
  • Ji-Ae Park,
  • Se Jong Oh,
  • Misun Park,
  • Junhye Kwon,
  • Ui Sup Shin and
  • Eun Ho Kim
  • + 9 authors+ 4 authors

12 December 2019

Colorectal cancer (CRC) is a major cause of mortality that can be treated effectively with chemotherapy and radiotherapy, although resistance to these therapeutic modalities often occurs. Tumor-treating fields (TTFields) can block tumor growth by sel...

(This article belongs to the Collection Drug Resistance and Novel Therapies in Cancers)
  • Review
  • Open Access
851 Views
30 Pages

Tumor Treating Fields and the Glioblastoma Microenvironment: Mechanistic Convergences with Radiotherapy

  • Flavio Donnini,
  • Giuseppe Battaglia,
  • Salvatore Chibbaro,
  • Francesco Marampon and ,
  • Giuseppe Minniti and
  • Paolo Tini
  • + 1 author+ 0 author

25 June 2026

Glioblastoma (GBM) remains the most lethal primary brain tumor in adults, with a median overall survival of approximately 15–20 months despite multimodal treatment including surgery, chemoradiation, and Tumor Treating Fields (TTFields). While t...

(This article belongs to the Section Methods and Technologies Development)
  • Review
  • Open Access
10 Citations
7,295 Views
21 Pages

Tumor Treating Fields and Combination Therapy in Management of Brain Oncology

  • Ruisi Nicole Liu,
  • James H. Huang,
  • Xiaoming Qi,
  • Yizhong Pan and ,
  • Erxi Wu and
  • Damir Nizamutdinov
  • + 1 author+ 0 author

2 April 2025

Glioblastoma (GBM) remains a challenging cancer to treat with limited effective therapies. Standard treatments, including surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy, offer marginal survival benefits but are often limited...

(This article belongs to the Special Issue Combination Therapies for Brain Tumors)
  • Article
  • Open Access
14 Citations
5,252 Views
16 Pages

Real-Time Monitoring of the Effect of Tumour-Treating Fields on Cell Division Using Live-Cell Imaging

  • Hoa T. Le,
  • Michael Staelens,
  • Davide Lazzari,
  • Gordon Chan and
  • Jack A. Tuszyński

31 August 2022

The effects of electric fields (EFs) on various cell types have been thoroughly studied, and exhibit a well-known regulatory effect on cell processes, implicating their usage in several medical applications. While the specific effect exerted on cells...

(This article belongs to the Section Cellular Biophysics)
  • Article
  • Open Access
20 Citations
4,667 Views
18 Pages

Genome-Wide Expression and Anti-Proliferative Effects of Electric Field Therapy on Pediatric and Adult Brain Tumors

  • Joshua Branter,
  • Maria Estevez-Cebrero,
  • Mohammed Diksin,
  • Michaela Griffin and ,
  • Marcos Castellanos-Uribe,
  • Sean May,
  • Ruman Rahman,
  • Richard Grundy,
  • Surajit Basu and
  • Stuart Smith
  • + 5 authors+ 0 author

11 February 2022

The lack of treatment options for high-grade brain tumors has led to searches for alternative therapeutic modalities. Electrical field therapy is one such area. The Optune™ system is an FDA-approved novel device that delivers continuous alterna...

(This article belongs to the Special Issue Frontiers in Neuro-Oncology)
  • Article
  • Open Access
2 Citations
2,327 Views
15 Pages

Tumor-Treating Fields Alter Nanomechanical Properties of Pancreatic Ductal Adenocarcinoma Cells Co-Cultured with Extracellular Matrix

  • Tanmay Kulkarni,
  • Sreya Banik,
  • Debabrata Mukhopadhyay,
  • Hani Babiker and
  • Santanu Bhattacharya

Tumor-Treating Fields (TTFields), a novel therapeutic avenue, is approved for therapy in Glioblastoma multiforme, malignant pleural mesothelioma, and metastatic non-small cell lung cancer (NSCLC). In pancreatic ductal adenocarcinoma (PDAC), several c...

(This article belongs to the Section Biomaterials for Cancer Therapies)
  • Review
  • Open Access
5 Citations
8,583 Views
14 Pages

Pediatric primary brain tumors pose significant therapeutic challenges due to their aggressive nature and the critical environment of the developing brain. Traditional modalities like surgery, chemotherapy, and radiotherapy often achieve limited succ...

(This article belongs to the Special Issue Clinical Outcomes and New Treatments in Pediatric Brain Tumors)
  • Correction
  • Open Access
1 Citations
1,900 Views
3 Pages

Correction: Davidi et al. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo. Cancers 2022, 14, 2959

  • Shiri Davidi,
  • Sara Jacobovitch,
  • Anna Shteingauz,
  • Antonia Martinez-Conde and ,
  • Ori Braten,
  • Catherine Tempel-Brami,
  • Einav Zeevi,
  • Roni Frechtel-Gerzi,
  • Hila Ene and
  • Yoram Palti
  • + 12 authors+ 7 authors

13 February 2023

The authors wish to make minor corrections to Figure 1 and Figure 2 of the following paper [...]

  • Review
  • Open Access
19 Citations
7,955 Views
26 Pages

Revolutionizing Brain Tumor Care: Emerging Technologies and Strategies

  • Trang T. T. Nguyen,
  • Lloyd A. Greene,
  • Hayk Mnatsakanyan and
  • Christian E. Badr

Glioblastoma multiforme (GBM) is one of the most aggressive forms of brain tumor, characterized by a daunting prognosis with a life expectancy hovering around 12–16 months. Despite a century of relentless research, only a select few drugs have...

(This article belongs to the Special Issue Glioblastoma: Pathogenetic, Diagnostic and Therapeutic Perspectives)
  • Review
  • Open Access
56 Citations
8,333 Views
24 Pages

5 December 2018

To date, no targeted drugs, antibodies or combinations of chemotherapeutics have been demonstrated to be more efficient than temozolomide, or to increase efficacy of standard therapy (surgery, radiotherapy, temozolomide, steroid dexamethasone). Accor...

(This article belongs to the Special Issue Glioblastoma: State of the Art and Future Perspectives)
  • Review
  • Open Access
279 Citations
17,455 Views
13 Pages

The standard of care (SOC) for high-grade gliomas (HGG) is maximally safe surgical resection, followed by concurrent radiation therapy (RT) and temozolomide (TMZ) for 6 weeks, then adjuvant TMZ for 6 months. Before this SOC was established, glioblast...

(This article belongs to the Special Issue Comprehensive Overview of Treatments for the Most Common Adult Central Nervous System Neoplasms)
  • Article
  • Open Access
30 Citations
5,684 Views
19 Pages

Rapalink-1 Targets Glioblastoma Stem Cells and Acts Synergistically with Tumor Treating Fields to Reduce Resistance against Temozolomide

  • Andres Vargas-Toscano,
  • Ann-Christin Nickel,
  • Guanzhang Li,
  • Marcel Alexander Kamp and ,
  • Sajjad Muhammad,
  • Gabriel Leprivier,
  • Ellen Fritsche,
  • Roger A. Barker,
  • Michael Sabel and
  • Ulf Dietrich Kahlert
  • + 8 authors+ 3 authors

21 December 2020

Glioblastoma (GBM) is a lethal disease with limited clinical treatment options available. Recently, a new inhibitor targeting the prominent cancer signaling pathway mTOR was discovered (Rapalink-1), but its therapeutic potential on stem cell populati...

(This article belongs to the Special Issue Cancer Stem Cells and Therapy Resistance)
  • Review
  • Open Access
187 Citations
19,910 Views
17 Pages

Glioblastoma: Clinical Presentation, Multidisciplinary Management, and Long-Term Outcomes

  • David Sipos,
  • Bence L. Raposa,
  • Omar Freihat,
  • Mihály Simon and ,
  • Nejc Mekis,
  • Patrizia Cornacchione and
  • Árpád Kovács
  • + 2 authors+ 0 author

5 January 2025

Glioblastoma, the most common and aggressive primary brain tumor in adults, presents a formidable challenge due to its rapid progression, treatment resistance, and poor survival outcomes. Standard care typically involves maximal safe surgical resecti...

(This article belongs to the Special Issue Outcomes in Glioblastoma Patients: From Diagnosis to Palliation)
  • Article
  • Open Access
2 Citations
5,020 Views
23 Pages

FGFR1 Inhibition by Pemigatinib Enhances Radiosensitivity in Glioblastoma Stem Cells Through S100A4 Downregulation

  • Valérie Gouazé-Andersson,
  • Caroline Delmas,
  • Yvan Nicaise,
  • Julien Nicolau and ,
  • Juan Pablo Cerapio and
  • Elizabeth Cohen-Jonathan Moyal
  • + 1 author+ 0 author

11 September 2025

Glioblastoma (GBM) is an aggressive and highly heterogeneous tumor that frequently recurs despite surgery followed by radio-chemotherapy and, more recently, TTFields. This recurrence is largely driven by glioblastoma stem cells (GSCs), which are intr...

(This article belongs to the Special Issue Neuro-Oncological Advances in Stem Cell Research: A New Era in Brain Tumor Therapy)
  • Article
  • Open Access
4 Citations
4,608 Views
25 Pages

Intratumoral Treatment in Lung Cancer: Is It Time to Move Towards Clinical Practice?

  • Gabriele Giuseppe Pagliari,
  • Francesca Colonese,
  • Stefania Canova,
  • Maria Ida Abbate and ,
  • Luca Sala,
  • Francesco Petrella,
  • Thoma Dario Clementi and
  • Diego Luigi Cortinovis
  • + 3 authors+ 0 author

21 November 2024

According to a modern view, cancer no longer follows a purely mechanistic model. Rather, a tumor is conceived as a more complex structure, composed of cancer cells, the activities of which may interact and reshape the so-called tumor microenvironment...

(This article belongs to the Section Cancer Therapy)
  • Review
  • Open Access
10 Citations
10,588 Views
27 Pages

Radiotherapy in Glioblastoma Multiforme: Evolution, Limitations, and Molecularly Guided Future

  • Castalia Fernández,
  • Raquel Ciérvide,
  • Ana Díaz,
  • Isabel Garrido and
  • Felipe Couñago

Glioblastoma multiforme (GBM), the most aggressive primary brain tumor in adults, has a poor prognosis due to rapid recurrence and treatment resistance. This review examines the evolution of radiotherapy (RT) for GBM management, from whole-brain RT t...

(This article belongs to the Section Cancer Biology and Oncology)